Who are epirubicin - cyclophosphamide / docetaxel + bevacizumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epirubicin-cyclophosphamide-docetaxel-bevacizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

epirubicin - cyclophosphamide / docetaxel + bevacizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

epirubicin - cyclophosphamide / docetaxel + bevacizumab (epirubicin - cyclophosphamide / docetaxel + bevacizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anthracycline antibiotic, alkylating agent, taxane, monoclonal antibody. Area: Oncology.

phase 3 anthracycline antibiotic, alkylating agent, taxane, monoclonal antibody topoisomerase II, DNA, microtubules, VEGF Oncology Small molecule Live · refreshed every 30 min

Target snapshot

epirubicin - cyclophosphamide / docetaxel + bevacizumab (epirubicin - cyclophosphamide / docetaxel + bevacizumab) — GBG Forschungs GmbH. Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), reducing angiogenesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
epirubicin - cyclophosphamide / docetaxel + bevacizumab TARGET	epirubicin - cyclophosphamide / docetaxel + bevacizumab	GBG Forschungs GmbH	phase 3	anthracycline antibiotic, alkylating agent, taxane, monoclonal antibody	topoisomerase II, DNA, microtubules, VEGF

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anthracycline antibiotic, alkylating agent, taxane, monoclonal antibody class)

GBG Forschungs GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). epirubicin - cyclophosphamide / docetaxel + bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/epirubicin-cyclophosphamide-docetaxel-bevacizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab